Join
Live feed
·
PRReleasevia Quantisnow
Wave Life Sciences Ltd. logo

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington's Disease

ByQuantisnow·Wall Street's wire, on your screen.
WVE· Wave Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WVE (Wave Life Sciences Ltd.) and more on Quantisnow.